EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Latest Developments in Imaging for Axial Disease in Psoriatic Arthritis

Walter P. Maksymowych

Canadian Rheumatology Today · 2025

DOI: 10.58931/crt.2025.2367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Rheumatology Today, 2025. Verfasst von Walter P. Maksymowych. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Axial disease in psoriatic arthritis (axPsA), affecting the sacroiliac joints (SIJ) and spine, is recognized as one of the domains in the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for psoriatic arthritis (PsA). Accurate recognition of this manifestation is crucial for comprehensive management of this disease. It is defined according to both clinical and imaging features. Clinically, inflammatory back pain (IBP) is a key feature; however, findings from a recent Canadian inception cohort study—Screening for Axial Spondyloarthritis in Psoriasis, Iritis, or Colitis Cohorts 1 and 2 (SASPIC1 and 2)—which included patients with psoriasis and undiagnosed back pain, showed no differences in the frequency of IBP or non-steroidal anti-inflammatory drug (NSAID) responsiveness between those diagnosed with axPsA and individuals with other causes of chronic back pain. Similarly, data from the global Axial Involvement in Psoriatic Arthritis (AXIS) cohort revealed only minor numerical differences in NSAID responsiveness or frequency of IBP, according to the ASAS criteria, between participants with and without axial involvement when evaluated by central reviewers. Recent post-hoc studies of clinical trials in PsA have attempted to identify axPsA according to a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) threshold of ≥4. However, MRI-based assessment of axPsA in a large European cohort of 581 PsA patients, recruited across 17 European registries within the EuroSpA network, indicated that a BASDAI ≥4 did not discriminate PsA patients with axial disease from those without. Moreover, only 25–45% of patients with radiographic features of axPsA have been reported to have IBP, with some patients being clinically perceived as asymptomatic. Additionally, axSpA-based IBP criteria have demonstrated limited specificity for axPsA. Studies using MRI have reported poor correlation between sacroiliitis on imaging and both the presence and type of back pain.

Zitieren

APA

Maksymowych, W. P. (2025). Latest Developments in Imaging for Axial Disease in Psoriatic Arthritis. Canadian Rheumatology Today. https://doi.org/10.58931/crt.2025.2367

Vancouver

Maksymowych WP. Latest Developments in Imaging for Axial Disease in Psoriatic Arthritis. Canadian Rheumatology Today. 2025. doi:10.58931/crt.2025.2367

BibTeX
@article{Maksymowych2025,
  author = {Maksymowych, Walter P.},
  title = {Latest Developments in Imaging for Axial Disease in Psoriatic Arthritis},
  journal = {Canadian Rheumatology Today},
  year = {2025},
  doi = {10.58931/crt.2025.2367}
}
Kostenlos starten →